MAP2K7 and hepatocellular carcinoma: By inhibiting RAF/MEK/ERK signaling, sorafenib reduces the activation of downstream signaling molecules, such as ERK and AKT, which are crucial for tumor progression and resistance mechanisms in HCC [39, 40].